Immunotherapy with the anti-program death-1 (anti-PD-1) antibody can treat patients with gestational trophoblastic neoplasia who are resistant to the usual chemotherapeutics and offers a powerful new treatment with low toxicity. The gene discussed is PDCD1; the disease is gestational trophoblastic neoplasm.